PedAM
Pediatric Disease Annotations & Medicines
| Disease | ovarian cancer |
| Symptom | C0006142|breast cancer |
| Sentences | 27 |
| PubMedID- 25372568 | breast cancer following ovarian cancer in brca mutation carriers. |
| PubMedID- 23593081 | One pathogenic brca mutation (1/4, 25%) was detected in 4 breast cancer patients with an ovarian cancer family history. |
| PubMedID- 26389838 | breast cancer survivors' knowledge of hereditary breast and ovarian cancer following genetic counseling: an exploration of general and survivor-specific knowledge items. |
| PubMedID- 21559243 | Amongst the asian countries, pakistan has one of the highest rates of breast and ovarian cancer with breast cancer being the most common and ovarian the third most common malignancy amongst pakistani women and the most common cancer of gynecological origin in pakistan . |
| PubMedID- 23539753 | These data help counselling women from brca1/2 negative families with breast cancer that their risk of invasive ovarian cancer is not higher than the general population. |
| PubMedID- 23354980 | Women with brca mutations develop breast cancer in 50–80 % of cases and ovarian cancer in 10–40 % of cases. |
| PubMedID- 23372765 | Until recently, brca1 and brca2 were the only genes known to confer a considerable risk of ovarian cancer (in conjunction with breast cancer) with two recent studies reporting that 13.3–14.1% of unselected high grade ovarian cancers are accounted for by mutations in one of these two genes . |
| PubMedID- 19900968 | For example, breast cancer clusters with ovarian cancer and prostate cancer. |
| PubMedID- 24273914 | The first patient, whose mother suffered from breast and ovarian cancer, was diagnosed with left breast cancer in 2004. |
| PubMedID- 25138101 | It is difficult to predict what would be the effect of this on the results observed in this study, but in previously published dutch data, the prevalence of breast cancer patients with ovarian cancer in the family was only 2%.37 that same study reported 34% of breast cancer patients to have a family history of breast cancer to the extent of a cgc referral indication;37 higher than the 19% in our study, this difference likely being explained by our younger population. |
| PubMedID- 25525571 | We will discuss the genetic anomalies and syndromes that may cause ovarian cancers with emphasis on breast cancer type 1/2 mutations. |
| PubMedID- 19864120 | Synchronous ovarian cancer in a patient with pleomorphic lobular breast cancer: a therapeutic dilemma. |
| PubMedID- 20961453 | In some studies, only unaffected mutation-positive women were included and followed up; whilst in others--particularly when examining ovarian cancer risk--women with breast cancer were included. |
| PubMedID- 20569256 | While the cys61gly mutation appeared underrepresented in ovarian cancer as compared with breast cancer cases from the same population (p = 0.01), the 4153dela mutation made a higher contribution to ovarian cancer than to breast cancer (p < 0.01). |
| PubMedID- 22044796 | Gemcitabine is currently approved for the treatment of ovarian cancer (with carboplatin), breast cancer (with paclitaxel), non-small cell lung cancer (with cisplatin), and pancreatic cancer. |
| PubMedID- 21603858 | Germ-line brca2 mutations are involved in about 30% specific female breast cancer families, 20–25% of breast/ovarian cancer families, and 50–80% of male/female breast cancer families . |
| PubMedID- 24853100 | We investigated genetic anticipation of breast or ovarian cancer in patients with familial breast cancer. |
| PubMedID- 20850174 | For nonmucinous invasive cancers, jewish ethnicity, parity, prior breast cancer, and family history of breast or ovarian cancer predicted higher ca125, and greater body mass index (bmi), recurrent yeast infections, colitis, and appendectomy predicted lower ca125. |
| PubMedID- 25848941 | Mutations confer a high risk of breast and ovarian cancer with estimated breast cancer penetrances of 60% for brca1 and 55% for brca2 by age 70 years . |
| PubMedID- 25490378 | Recent studies support the following conclusions: first, oral contraceptive use reduces ovarian cancer risk without significantly increasing breast cancer risk, second, salpingo-oophorectomy leads to a reduction in ovarian cancer, breast cancer, and overall mortality for women who are carriers of brca1 and brca2 mutations, and third, the 'ovarian cancers' associated with brca mutations actually include fallopian tube and peritoneal cancer and may have a precursor lesion in the fallopian tube; this observation has prompted the provocative suggestion of removing the fallopian tube to reduce ovarian cancer risk. |
| PubMedID- 24957768 | breast cancer and 80% of ovarian cancers are of epithelial origin and the most characteristic tacas in these cancers are sialyllex (slex), sialyllea (slea ), and ley, occurring in most human epithelial tissues . |
| PubMedID- 23316241 | There is a risk of developing a metachronous ovarian cancer for women with early onset breast cancer (younger than 40 years old) or who have a family history of breast or ovarian cancer or women who are brca1 mutation carriers . |
| PubMedID- 26579492 | ovarian cancer together with pancreatic and breast cancers have been defined as the top three cancers in which dna repair pathways are defective (20). |
| PubMedID- 21370594 | Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer. |
| PubMedID- 22415235 | Recently, another member of the rad51 family of paralogs, rad51d, was found to be mutated in women affected by familial ovarian cancer, with or without breast cancer. |
| PubMedID- 21939546 | Family b-2002 (figure 4) is a breast/ovarian cancer family, with four breast cancer cases at 43, 43, 52 and 55 years old (mean age: 48.3) and one ovarian cancer at age 52. controlateral breast cancer occurred in two patients (ii-1 and ii-13). |
| PubMedID- 20880789 | Thus, the frequency of synchronous primary ovarian cancer in patients with breast cancer who underwent screening was 0.5%. |
Page: 1